{"disease":{"id":"her2-positive-early-stage-breast-cancer","name":"her2 positive early stage breast cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04109391","title":"Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":338,"lead_sponsor_name":"Tanvex BioPharma USA, Inc.","has_results":true},{"nct_id":"NCT06035016","title":"Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT07402473","title":"EUREKA Study:Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}